Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ye, J.-M.
Right arrow Articles by Kraegen, E. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ye, J.-M.
Right arrow Articles by Kraegen, E. W.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:411-417, 2001
© 2001 by the American Diabetes Association, Inc.

Peroxisome Proliferator—Activated Receptor (PPAR)-{alpha} Activation Lowers Muscle Lipids and Improves Insulin Sensitivity in High Fat—Fed Rats

Comparison With PPAR-{gamma} Activation

Ji-Ming Ye, Patrick J. Doyle, Miguel A. Iglesias, David G. Watson, Gregory J. Cooney, and Edward W. Kraegen

From the Garvan Institute of Medical Research (J.-M.Y., M.A.I., D.G.W., G.J.C., E.W.K.), Sydney, Australia; and Novo Nordisk A/S (P.J.D.), Bagsverd, Denmark.

Address correspondence and reprint requests to Ji-Ming Ye, PhD, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, NSW 2010, Australia. E-mail: j.ye{at}garvan.unsw.edu.au . P.J.D. is currently affiliated with F.Hoffman La-Roche, PRBM, Basel, Switzerland.

Peroxisome proliferator—activated receptor (PPAR)-{alpha} agonists lower circulating lipids, but the consequences for muscle lipid metabolism and insulin sensitivity are not clear. We investigated whether PPAR-{alpha} activation improves insulin sensitivity in insulin-resistant rats and compared the effects with PPAR-{gamma} activation. Three-week high fat-fed male Wistar rats were untreated or treated with the specific PPAR-{alpha} agonist WY14643 or the PPAR-{gamma} agonist pioglitazone (both 3 mg · kg-1 · day-1) for the last 2 weeks of high-fat feeding. Like pioglitazone, WY14643 lowered basal plasma levels of glucose, triglycerides (-16% vs. untreated), and leptin (-52%), and also muscle triglyceride (-34%) and total long-chain acyl-CoAs (LCACoAs) (-41%) (P < 0.05). In contrast to pioglitazone, WY14643 substantially reduced visceral fat weight and total liver triglyceride content (P < 0.01) without increasing body weight gain. WY14643 and pioglitazone similarly enhanced wholebody insulin sensitivity (clamp glucose infusion rate increased 35 and 37% and glucose disposal 22 and 15%, respectively, vs. untreated). Both agents enhanced insulin-mediated muscle glucose metabolic index (Rg') and reduced muscle triglyceride and LCACoA accumulation (P < 0.05). Although pioglitazone had more potent effects than WY14643 on muscle insulin sensitization, this was associated with its greater effect to reduce muscle LCACoA accumulation. Overall insulin-mediated muscle Rg' was inversely correlated with the content of LCACoAs (r = -0.74, P = 0.001) and with plasma triglyceride levels (r = -0.77, P < 0.001). We conclude that even though WY14643 and pioglitazone, representing PPAR-{alpha} and PPAR-{gamma} activation, respectively, may alter muscle lipid supply by different mechanisms, both significantly improve muscle insulin action in the high fat—fed rat model of insulin resistance, and this effect is proportional to the degree to which they reduce muscle lipid accumulation.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
S. M. Hofmann, D. Perez-Tilve, T. M. Greer, B. A. Coburn, E. Grant, J. E. Basford, M. H. Tschop, and D. Y. Hui
Defective Lipid Delivery Modulates Glucose Tolerance and Metabolic Response to Diet in Apolipoprotein E Deficient Mice
Diabetes, January 1, 2008; 57(1): 5 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. C. Noland, J. P. Thyfault, S. T. Henes, B. R. Whitfield, T. L. Woodlief, J. R. Evans, J. A. Lust, S. L. Britton, L. G. Koch, R. W. Dudek, et al.
Artificial selection for high-capacity endurance running is protective against high-fat diet-induced insulin resistance
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E31 - E41.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. Andrulionyte, T. Kuulasmaa, J.-L. Chiasson, M. Laakso, and for the STOP-NIDDM Study Group
Single Nucleotide Polymorphisms of the Peroxisome Proliferator-Activated Receptor-{alpha} Gene (PPARA) Influence the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial
Diabetes, April 1, 2007; 56(4): 1181 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Sheikh, G. Camejo, B. Lanne, T. Halvarsson, M. R. Landergren, and N. D. Oakes
Beyond lipids, pharmacological PPAR{alpha} activation has important effects on amino acid metabolism as studied in the rat
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1157 - E1165.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, et al.
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1213 - E1222.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. P Corcoran, S. Lamon-Fava, and R. A Fielding
Skeletal muscle lipid deposition and insulin resistance: effect of dietary fatty acids and exercise
Am. J. Clinical Nutrition, March 1, 2007; 85(3): 662 - 677.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J.-M. Ye, N. Dzamko, A. J. Hoy, M. A. Iglesias, B. Kemp, and E. Kraegen
Rosiglitazone Treatment Enhances Acute AMP-Activated Protein Kinase-Mediated Muscle and Adipose Tissue Glucose Uptake in High-Fat-Fed Rats.
Diabetes, October 1, 2006; 55(10): 2797 - 2804.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
O. Mezei, Y. Li, E. Mullen, J. S. Ross-Viola, and N. F. Shay
Dietary isoflavone supplementation modulates lipid metabolism via PPAR{alpha}-dependent and -independent mechanisms
Physiol Genomics, September 14, 2006; 26(1): 8 - 14.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. J. Yoon, G. Y. Lee, J.-J. Chung, Y. H. Ahn, S. H. Hong, and J. B. Kim
Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor {alpha}
Diabetes, September 1, 2006; 55(9): 2562 - 2570.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Bergeron, J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, B. B. Zhang, D. E. Moller, et al.
Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism
Endocrinology, September 1, 2006; 147(9): 4252 - 4262.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Knauf, J. Rieusset, M. Foretz, P. D. Cani, M. Uldry, M. Hosokawa, E. Martinez, M. Bringart, A. Waget, S. Kersten, et al.
Peroxisome Proliferator-Activated Receptor-{alpha}-Null Mice Have Increased White Adipose Tissue Glucose Utilization, GLUT4, and Fat Mass: Role in Liver and Brain
Endocrinology, September 1, 2006; 147(9): 4067 - 4078.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
I. Duivenvoorden, P. J Voshol, P. C. Rensen, W. van Duyvenvoorde, J. A Romijn, J. J Emeis, L. M Havekes, and W. F Nieuwenhuizen
Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice.
Am. J. Clinical Nutrition, August 1, 2006; 84(2): 312 - 321.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. S. Lee, W. S. Kim, K. H. Kim, M. J. Yoon, H. J. Cho, Y. Shen, J.-M. Ye, C. H. Lee, W. K. Oh, C. T. Kim, et al.
Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States.
Diabetes, August 1, 2006; 55(8): 2256 - 2264.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
A. T. De Souza, P. D. Cornwell, X. Dai, M. J. Caguyong, and R. G. Ulrich
Agonists of the Peroxisome Proliferator-Activated Receptor Alpha Induce a Fiber-Type-Selective Transcriptional Response in Rat Skeletal Muscle
Toxicol. Sci., August 1, 2006; 92(2): 578 - 586.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. Lalloyer, B. Vandewalle, F. Percevault, G. Torpier, J. Kerr-Conte, M. Oosterveer, R. Paumelle, J.-C. Fruchart, F. Kuipers, F. Pattou, et al.
Peroxisome Proliferator-Activated Receptor {alpha} Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets
Diabetes, June 1, 2006; 55(6): 1605 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Desvergne, L. Michalik, and W. Wahli
Transcriptional Regulation of Metabolism
Physiol Rev, April 1, 2006; 86(2): 465 - 514.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning
Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1
Endocrinology, February 1, 2006; 147(2): 875 - 884.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Tsuchida, T. Yamauchi, S. Takekawa, Y. Hada, Y. Ito, T. Maki, and T. Kadowaki
Peroxisome Proliferator-Activated Receptor (PPAR){alpha} Activation Increases Adiponectin Receptors and Reduces Obesity-Related Inflammation in Adipose Tissue: Comparison of Activation of PPAR{alpha}, PPAR{gamma}, and Their Combination
Diabetes, December 1, 2005; 54(12): 3358 - 3370.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. D. Oakes, P. Thalen, T. Hultstrand, S. Jacinto, G. Camejo, B. Wallin, and B. Ljung
Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R938 - R946.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Reifel-Miller, K. Otto, E. Hawkins, R. Barr, W. R. Bensch, C. Bull, S. Dana, K. Klausing, J.-A. Martin, R. Rafaeloff-Phail, et al.
A Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia
Mol. Endocrinol., June 1, 2005; 19(6): 1593 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. G. Moesgaard, C. L. Brand, J. Sturis, B. Ahren, M. Wilken, J. Fleckner, R. D. Carr, O. Svendsen, A. J. Hansen, and D. X. Gram
Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats
Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1137 - E1145.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
H. K. Ortmeyer, Y. Adall, K. R. Marciani, A. Katsiaras, A. S. Ryan, N. L. Bodkin, and B. C. Hansen
Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-{alpha} agonist (K-111) administration in rhesus monkeys
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1509 - R1517.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. K. Vikramadithyan, K. Hirata, H. Yagyu, Y. Hu, A. Augustus, S. Homma, and I. J. Goldberg
Peroxisome Proliferator-Activated Receptor Agonists Modulate Heart Function in Transgenic Mice with Lipotoxic Cardiomyopathy
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 586 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Rasouli, U. Raue, L. M. Miles, T. Lu, G. B. Di Gregorio, S. C. Elbein, and P. A. Kern
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue
Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E930 - E934.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Noushmehr, E. D'Amico, L. Farilla, H. Hui, K. A. Wawrowsky, W. Mlynarski, A. Doria, N. A. Abumrad, and R. Perfetti
Fatty Acid Translocase (FAT/CD36) Is Localized on Insulin-Containing Granules in Human Pancreatic {beta}-Cells and Mediates Fatty Acid Effects on Insulin Secretion
Diabetes, February 1, 2005; 54(2): 472 - 481.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. M. Flavell, H. Ireland, J. W. Stephens, E. Hawe, J. Acharya, H. Mather, S. J. Hurel, and S. E. Humphries
Peroxisome Proliferator-Activated Receptor {alpha} Gene Variation Influences Age of Onset and Progression of Type 2 Diabetes
Diabetes, February 1, 2005; 54(2): 582 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Knouff and J. Auwerx
Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology
Endocr. Rev., December 1, 2004; 25(6): 899 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. C. Li and C. K. Glass
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
J. Lipid Res., December 1, 2004; 45(12): 2161 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What is the cause and effect?
Diabetes Care, September 1, 2004; 27(9): 2253 - 2259.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Yajima, E. Ikeshima, M. Shiraki, T. Kanaya, D. Fujiwara, H. Odai, N. Tsuboyama-Kasaoka, O. Ezaki, S. Oikawa, and K. Kondo
Isohumulones, Bitter Acids Derived from Hops, Activate Both Peroxisome Proliferator-activated Receptor {alpha} and {gamma} and Reduce Insulin Resistance
J. Biol. Chem., August 6, 2004; 279(32): 33456 - 33462.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
P. Benatti, G. Peluso, R. Nicolai, and M. Calvani
Polyunsaturated Fatty Acids: Biochemical, Nutritional and Epigenetic Properties
J. Am. Coll. Nutr., August 1, 2004; 23(4): 281 - 302.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. D. Hegarty, S. M. Furler, N. D. Oakes, E. W. Kraegen, and G. J. Cooney
Peroxisome Proliferator-Activated Receptor (PPAR) Activation Induces Tissue-Specific Effects on Fatty Acid Uptake and Metabolism in Vivo--A Study Using the Novel PPAR{alpha}/{gamma} Agonist Tesaglitazar
Endocrinology, July 1, 2004; 145(7): 3158 - 3164.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. Desvergne, L. Michalik, and W. Wahli
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Mol. Endocrinol., June 1, 2004; 18(6): 1321 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Haluzik, O. Gavrilova, and D. LeRoith
Peroxisome Proliferator-Activated Receptor-{alpha} Deficiency Does Not Alter Insulin Sensitivity in Mice Maintained on Regular or High-Fat Diet: Hyperinsulinemic-Euglycemic Clamp Studies
Endocrinology, April 1, 2004; 145(4): 1662 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. den Boer, P.J. Voshol, F. Kuipers, L.M. Havekes, and J.A. Romijn
Hepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models
Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 644 - 649.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Ferre
The Biology of Peroxisome Proliferator-Activated Receptors: Relationship With Lipid Metabolism and Insulin Sensitivity
Diabetes, February 1, 2004; 53(90001): S43 - 50.
[Abstract] [Full Text]

Home page
 DiabetesHome page
M. C. Sugden and M. J. Holness
Potential Role of Peroxisome Proliferator-Activated Receptor-{alpha} in the Modulation of Glucose-Stimulated Insulin Secretion
Diabetes, February 1, 2004; 53(90001): S71 - 81.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
K. Levin, O. Hother-Nielsen, J. E. Henriksen, and H. Beck-Nielsen
Effects of Troglitazone in Young First-Degree Relatives of Patients With Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. P. Russell, J. Feilchenfeldt, S. Schreiber, M. Praz, A. Crettenand, C. Gobelet, C. A. Meier, D. R. Bell, A. Kralli, J.-P. Giacobino, et al.
Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-{gamma} Coactivator-1 and Peroxisome Proliferator-Activated Receptor-{alpha} in Skeletal Muscle
Diabetes, December 1, 2003; 52(12): 2874 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. H. Koh, M.-S. Kim, J.-Y. Park, H. S. Kim, J.-Y. Youn, H.-S. Park, J. H. Youn, and K.-U. Lee
Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Activation Prevents Diabetes in OLETF Rats: Comparison With PPAR-{gamma} Activation
Diabetes, September 1, 2003; 52(9): 2331 - 2337.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Kim, M. Haluzik, Z. Asghar, D. Yau, J. W. Joseph, A. M. Fernandez, M. L. Reitman, S. Yakar, B. Stannard, L. Heron-Milhavet, et al.
Peroxisome Proliferator-Activated Receptor-{alpha} Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis
Diabetes, July 1, 2003; 52(7): 1770 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
J. Busserolles, E. Gueux, E. Rock, C. Demigne, A. Mazur, and Y. Rayssiguier
Oligofructose Protects against the Hypertriglyceridemic and Pro-oxidative Effects of a High Fructose Diet in Rats
J. Nutr., June 1, 2003; 133(6): 1903 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. L. Brand, J. Sturis, C. F. Gotfredsen, J. Fleckner, C. Fledelius, B. F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats
Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E841 - E854.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J.-M. Ye, M. A. Iglesias, D. G. Watson, B. Ellis, L. Wood, P. B. Jensen, R. V. Sorensen, P. J. Larsen, G. J. Cooney, K. Wassermann, et al.
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly
Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E531 - E540.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
I. Pineda Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels
Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor {alpha} Gene via Activation of the Farnesoid X Receptor
Mol. Endocrinol., February 1, 2003; 17(2): 259 - 272.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Kautzky-Willer, M. Krssak, C. Winzer, G. Pacini, A. Tura, S. Farhan, O. Wagner, G. Brabant, R. Horn, H. Stingl, et al.
Increased Intramyocellular Lipid Concentration Identifies Impaired Glucose Metabolism in Women With Previous Gestational Diabetes
Diabetes, February 1, 2003; 52(2): 244 - 251.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. C. Sugden, G. K. Greenwood, N. D. Smith, and M. J. Holness
Peroxisome Proliferator-Activated Receptor-{alpha} Activation during Pregnancy Attenuates Glucose-Stimulated Insulin Hypersecretion in Vivo by Increasing Insulin Sensitivity, without Impairing Pregnancy-Induced Increases in {beta}-Cell Glucose Sensing and Responsiveness
Endocrinology, January 1, 2003; 144(1): 146 - 153.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Qi, L. Kazdova, V. Zidek, V. Landa, V. Kren, H. A. Pershadsingh, E. St. Lezin, N. A. Abumrad, M. Pravenec, and T. W. Kurtz
Pharmacogenetic Evidence That Cd36 Is a Key Determinant of the Metabolic Effects of Pioglitazone
J. Biol. Chem., December 6, 2002; 277(50): 48501 - 48507.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J.-M. Ye, G. Frangioudakis, M. A. Iglesias, S. M. Furler, B. Ellis, N. Dzamko, G. J. Cooney, and E. W. Kraegen
Prior Thiazolidinedione Treatment Preserves Insulin Sensitivity in Normal Rats during Acute Fatty Acid Elevation: Role of the Liver
Endocrinology, December 1, 2002; 143(12): 4527 - 4535.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
B. Ljung, K. Bamberg, B. Dahllof, A. Kjellstedt, N. D. Oakes, J. Ostling, L. Svensson, and G. Camejo
AZ 242, a novel PPAR{alpha}/{gamma} agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats
J. Lipid Res., November 1, 2002; 43(11): 1855 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Aasum, D. D. Belke, D. L. Severson, R. A. Riemersma, M. Cooper, M. Andreassen, and T. S. Larsen
Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator
Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H949 - H957.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.